Editas Medicine Announces First Quarter 2021 Results and Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. TLT

Go back to Editas Medicine Announces First Quarter 2021 Results and Update

Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat

May 5, 2021 7:24 AM EDT

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.86), $0.13 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $5.77 million.

Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage... More